
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
The Department of Health and Human Services announcedsome Medicare beneficiaries soon will be entitled to two foot exams a year